Indaptus Therapeutics, Inc. Increase (Decrease) in Other Current Liabilities
Indaptus Therapeutics, Inc. (INDP) reported Increase (Decrease) in Other Current Liabilities of -$5.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2026-08-13
- Indaptus Therapeutics, Inc. increase (decrease) in other current liabilities for the quarter ending 2026-06-30 was -$317.57K.
- Indaptus Therapeutics, Inc. increase (decrease) in other current liabilities for the quarter ending 2026-03-31 was -$5.23M.
- Indaptus Therapeutics, Inc. increase (decrease) in other current liabilities for the quarter ending 2025-06-30 was -$571.69K.
- Indaptus Therapeutics, Inc. increase (decrease) in other current liabilities for the quarter ending 2025-03-31 was -$762.34K.
- Indaptus Therapeutics, Inc. increase (decrease) in other current liabilities for fiscal 2025 was $2.85M, a 500.95% increase from fiscal 2024.
- Indaptus Therapeutics, Inc. increase (decrease) in other current liabilities for fiscal 2024 was $474.06K.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 12 month |
|---|---|---|---|
| 2026-06-30 | -$317.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$5.54M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$5.23M 10-Q · filed 2026-05-15 | ||
| 2025-12-31 | $2.85M 10-K · filed 2026-03-17 | ||
| 2025-06-30 | -$571.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.33M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | -$762.34K 10-Q · filed 2026-05-15 | ||
| 2024-12-31 | $474.06K 10-K · filed 2026-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |